Clinical Trial Update: A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma [Phase 1, Phase 2]

View source ↗

Summary

This update reports on a Phase 1/2 clinical trial evaluating the MEK inhibitor mirdametinib in combination with palbociclib for liposarcoma, and notes that the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dedifferentiated Liposarcoma
• Myxoid Liposarcoma
• Myxoid Pleomorphic Liposarcoma
• Pleomorphic Liposarcoma
• Round Cell Liposarcoma
• Unresectable Dedifferentiated Liposarcoma
• Unresectable Liposarcoma
• Well-differentiated Liposarcoma

Drugs mentioned

• Mirdametinib (mirdametinib)
• Palbociclib (palbociclib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Well Differentiated Liposarcoma, Dedifferentiated Liposarcoma | Phase 1, Phase 2 | Status: RECRUITING